title: [Role of soluble Fas ligand in myocardial remodeling, severity and outcomes of chronic heart failure].
abstract: OBJECTIVE
  to reveal the specific features of Fas ligand-mediated ischemic myocardial remodeling and those of chronic heart failure (CHF) development during a 12-month prospective follow-up.
  
  
  METHODS
  A total of 94 patients with ischemic CHF were examined and divided into 3 groups according to NYHA Functional Class (FC): 1) FC II CHF in 35 patients; 2) FC III CHF in 31; 3) FC IV CHF in 28. According to the results of the 12-month follow-up, the patients were randomized into 2 groups: A) 49 patients with a favorable course of cardiovascular disease and B) 45 patients with its poor course. Serum soluble Fas ligand (sFas-L) levels were measured by enzyme immunoassay.
  
  
  RESULTS
  In the patients with CHF, the baseline sFas-L levels substantially exceeded that in the control group by 3-6 times (p<0.01). In the men with the poor course of CHF, the baseline serum sFAS-L levels (85.94±4.14 pg/ml) were significantly higher than that in the favorable CHF group (107.33±5.13 pg/ml; р=0.0015). ROC analysis of the sensitivity and specificity of cardiovascular risk stratification according to sFAS-L levels revealed the high prognostic value of this marker - ROC-Area±S.E. was 0.75±0.05 (95% confidence interval, 0.60 to 0.81; p=0.0005). There was a statistically significant moderate correlation of left ventricular (LV) ejection fraction with sFAS-L concentrations and a moderate direct correlation between serum sFAS-L concentrations and LV remodeling parameters.
  
  
  CONCLUSIONS
  The serum level of sFas-L determines the development of ischemic LV remodeling and the severity of CHF, by increasing in proportion to the degree of disease progression. The determination of serum sFas-L levels assists in objectively estimating the severity of apoptosis and may be an important prognostic test to assess the course of CHF in patients with coronary heart disease.
authors.affiliation: FGBNU 'NII kardiologii', Tomsk, Rossija.
authors.forename: A T
authors.initials: AT
authors.lastname: Teplyakov
authors.affiliation: GBOU VPO 'Novosibirskij gosudarstvennyj meditsinskij universitet' Minzdrava Rossii, Novosibirsk, Rossija.
authors.forename: E N
authors.initials: EN
authors.lastname: Berezikova
authors.affiliation: GBOU VPO 'Novosibirskij gosudarstvennyj meditsinskij universitet' Minzdrava Rossii, Novosibirsk, Rossija.
authors.forename: S N
authors.initials: SN
authors.lastname: Shilov
authors.affiliation: FGBNU 'NII kardiologii', Tomsk, Rossija.
authors.forename: E V
authors.initials: EV
authors.lastname: Grakova
authors.affiliation: FGBNU 'NII kardiologii', Tomsk, Rossija.
authors.forename: Yu Yu
authors.initials: YY
authors.lastname: Torim
authors.affiliation: GBOU VPO 'Novosibirskij gosudarstvennyj meditsinskij universitet' Minzdrava Rossii, Novosibirsk, Rossija.
authors.forename: A V
authors.initials: AV
authors.lastname: Efremov
authors.affiliation: GBOU VPO 'Novosibirskij gosudarstvennyj meditsinskij universitet' Minzdrava Rossii, Novosibirsk, Rossija.
authors.forename: A A
authors.initials: AA
authors.lastname: Popova
authors.affiliation: GBOU VPO 'Novosibirskij gosudarstvennyj meditsinskij universitet' Minzdrava Rossii, Novosibirsk, Rossija.
authors.forename: M G
authors.initials: MG
authors.lastname: Pustovetova
authors.affiliation: GBOU VPO 'Novosibirskij gosudarstvennyj meditsinskij universitet' Minzdrava Rossii, Novosibirsk, Rossija.
authors.forename: A Yu
authors.initials: AY
authors.lastname: Sabirova
authors.affiliation: FGBNU 'NII kardiologii', Tomsk, Rossija.
authors.forename: K V
authors.initials: KV
authors.lastname: Kopyeva
mesh_terms: D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D053222:Fas Ligand Protein / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000150:complications; D011237:Predictive Value of Tests; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: D015415:Biomarkers; C505661:FASLG protein, human; D053222:Fas Ligand Protein